[1]姜 山,孙 阳,崔兆磊,等.SERPINB4在宫颈癌中的表达及其预后价值[J].医学信息,2023,36(12):1-7.[doi:10.3969/j.issn.1006-1959.2023.12.001]
　JIANG Shan,SUN Yang,CUI Zhao-lei,et al.Expression of SERPINB4 in Cervical Cancer and its Prognostic Value[J].Journal of Medical Information,2023,36(12):1-7.[doi:10.3969/j.issn.1006-1959.2023.12.001]
点击复制

SERPINB4在宫颈癌中的表达及其预后价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年12期
页码:
1-7
栏目:
生物信息学
出版日期:
2023-06-15

文章信息/Info

Title:
Expression of SERPINB4 in Cervical Cancer and its Prognostic Value
文章编号:
1006-1959（2023）12-0001-07
作者:
姜 山; 孙 阳; 崔兆磊; 等
（1.福建中医药大学中西医结合学院，福建 福州 350122；2.福建医科大学肿瘤临床医学院/福建省肿瘤医院妇科，福建 福州 350014；3.福建医科大学肿瘤临床医学院/福建省肿瘤医院检验科，福建 福州 350014）
Author(s):
JIANG Shan; SUN Yang; CUI Zhao-lei; et al.
(1.College of Integrative Medicine,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,Fujian,China; 2.Department of Gynecology,Clinical Oncology School of Fujian Medical University/Fujian Cancer Hospital,Fuzhou 350014,Fujian,China;3.Department of Clinical Laboratory,Clinical Oncology School of Fujian Medical University/Fujian Cancer Hospital,Fuzhou 350014,Fujian,China)
关键词:
宫颈癌; SERPINB4; 肿瘤免疫浸润; 预后; 免疫治疗靶点
Keywords:
Cervical cancer; SERPINB4; Tumor immune infiltration; Prognosis; Immunotherapy targets
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2023.12.001
文献标志码:
A
摘要:
目的 探讨丝氨酸蛋白酶抑制剂B4（SERPINB4）在宫颈癌中的表达与预后相关性，分析其在宫颈癌中与肿瘤免疫浸润的关系。方法 基于TCGA与GTEx数据库获取宫颈癌相关的表达数据和临床参数，分析SERPINB4在正常宫颈组织和宫颈癌组织中的表达水平与临床病理特征、肿瘤浸润免疫细胞，免疫检查点标志分子及对化疗药物敏感性之间的相关性。应用Kaplan-Meier生存分析方法与ROC曲线评估SERPINB4在宫颈癌中的预后价值，并将SERPINB4及其共同表达基因进行GO与KEGG富集分析，探讨SERPINB4在宫颈癌中可能调控的分子信号通路。结果 SERPINB4在宫颈癌组织中呈高度表达（P＜0.05）；SERPINB4与宫颈癌患者不良预后（P=0.035）及远处转移（P=0.0092）相关；6个TIICs与SERPINB4表达呈正相关，其表达与多个免疫检查点存在统计学意义；SERPINB4在免疫细胞评分、基质细胞评分和综合评分较低组均升高，并且在宫颈癌患者中SERPINB高表达对靶向药物敏感性较差；GO分析发现SERPINB4及共表达基因多富集在免疫相关功能的调控，KEGG通路富集显示SERPINB4及共表达基因可能参与调控cAMP信号通路。结论 与正常宫颈组织相比，在宫颈癌组织中SERPINB4的高表达与患者预后不良及肿瘤免疫浸润有关，SERPINB4可能是宫颈癌的预后分子标志物和潜在的免疫治疗靶点。
Abstract:
Objective To explore the correlation between the expression of serine protease inhibitor B4(SERPINB4) in cervical cancer and prognosis, and analyze its relationship with tumor immune infiltration in cervical cancer.Methods The expression data and clinical parameters related to cervical cancer were obtained based on TCGA and GTEx databases. The correlation between the expression level of SERPINB4 in normal cervical tissues and cervical cancer tissues and clinicopathological features, tumor infiltrating immune cells, immune checkpoint marker molecules and sensitivity to chemotherapeutic drugs was analyzed. Kaplan-Meier survival analysis and ROC curve were used to evaluate the prognostic value of SERPINB4 in cervical cancer. GO and KEGG enrichment analysis of SERPINB4 and its co-expressed genes were performed to explore the molecular signaling pathways that SERPINB4 might regulate in cervical cancer.Results SERPINB4 was highly expressed in cervical cancer tissues (P<0.05). SERPINB4 was associated with poor prognosis (P=0.035) and distant metastasis (P=0.0092). Six TIICs were positively correlated with SERPINB4 expression, and their expression was statistically significant with multiple immune checkpoints. SERPINB4 was increased in the lower immune cell score, stromal cell score and comprehensive score group, and the high expression of SERPINB in cervical cancer patients was less sensitive to targeted drugs. GO analysis showed that SERPINB4 and co-expressed genes were mostly enriched in the regulation of immune-related functions. KEGG pathway enrichment showed that SERPINB4 and co-expressed genes might be involved in the regulation of cAMP signaling pathway.Conclusion Compared with normal cervical tissues, the high expression of SERPINB4 in cervical cancer tissues is related to poor prognosis and tumor immune infiltration. SERPINB4 may be a prognostic molecular marker and potential immunotherapy target for cervical cancer.

参考文献/References:

[1]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.[2]Hill EK.Updates in Cervical Cancer Treatment[J].Clin Obstet Gynecol,2020,63(1):3-11.[3]Izuhara K,Yamaguchi Y,Ohta S,et al.Squamous Cell Carcinoma Antigen 2 (SCCA2, SERPINB4): An Emerging Biomarker for Skin Inflammatory Diseases[J].Int J Mol Sci,2018,19(4):1102.[4]Sun Y,Sheshadri N,Zong WX.SERPINB3 and B4:From biochemistry to biology[J].Semin Cell Dev Biol,2017,62:170-177.[5]Bao J,Pan G,Poncz M,et al.Serpin functions in host-pathogen interactions[J].Peer J,2018,6:e4557.[6]Bravo-Pérez C,Vicente V,Corral J.Management of antithrombin deficiency: an update for clinicians[J].Expert Rev Hematol,2019,12(6):397-405.[7]Jiang L,Wang YJ,Zhao J,et al.Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy[J].Cell,2020,183(5):1219-1233.[8]Mendioroz M,Puebla-Guedea M,Montero-Marín J,et al.Telomere length correlates with subtelomeric DNA methylation in long-term mindfulness practitioners[J].Sci Rep,2020,10(1):4564.[9]Wang WJ,Wang J,Ouyang C,et al.Overview of serpin B9 and its roles in cancer (Review)[J].Oncol Rep,2021,46(3):190.[10]Buskwofie A,David-West G,Clare CA.A Review of Cervical Cancer: Incidence and Disparities[J].J Natl Med Assoc,2020,112(2):229-232.[11]Suminami Y,Nagashima S,Vujanovic NL,et al.Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1[J].Br J Cancer,2000,82(4):981-989.[12]Muniz TP,Sorotsky H,Kanjanapan Y,et al.Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor?Like Melanoma[J].J Invest Dermatol,2021,141(10):2470-2479.[13]Kang SD,Chatterjee S,Alam S,et al.Effect of Productive Human Papillomavirus 16 Infection on Global Gene Expression in Cervical Epithelium[J].J Virol,2018,92(20):e01261-e01318.[14]Markovina S,Wang S,Henke LE,et al.Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer[J].Br J Cancer,2018,118(1):72-78.[15]Catanzaro JM,Sheshadri N,Pan JA,et al.Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4[J].Nat Commun,2014,5:3729.[16]Bader JE,Voss K,Rathmell JC.Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy[J].Mol Cell,2020,78(6):1019-1033.[17]Hinshaw DC,Shevde LA.The Tumor Microenvironment Innately Modulates Cancer Progression[J].Cancer Res,2019,79(18):4557-4566.[18]Xia Y,Rao L,Yao H,et al.Engineering Macrophages for Cancer Immunotherapy and Drug Delivery [J].Adv Mater,2020,32(40):e2002054.[19]Zhang H,Kong Q,Wang J,et al.Complex roles of cAMP-PKA-CREB signaling in cancer[J].Exp Hematol Oncol,2020,9(1):32.[20]Khannpnavar B,Mehta V,Qi C,et al.Structure and function of adenylyl cyclases,key enzymes in cellular signaling[J].Curr Opin Struct Biol,2020,63:34-41.

相似文献/References:

[1]廖加群,曹 雪,陈燕平,等.宫颈癌盆腔淋巴结转移分布及危险因素分析[J].医学信息,2018,31(03):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
　LIAO Jia-qun,CAO Xue,CHEN Yan-ping,et al.Distribution and Risk Factors of Pelvic Lymph Node Metastasis in Cervical Cancer[J].Journal of Medical Information,2018,31(12):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
[2]徐 洁.宫颈癌筛查及预防的研究进展[J].医学信息,2018,31(09):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
　XU Jie.Advances in Screening and Prevention of Cervical Cancer[J].Journal of Medical Information,2018,31(12):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
[3]黄 花,徐冬冬,章丽霞.TGF-β1在宫颈癌中的研究进展[J].医学信息,2018,31(12):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
　HUANG Hua,XU Dong-dong,ZHANG Li-xia.Research Progress of TGF-β1 in Cervical Cancer[J].Journal of Medical Information,2018,31(12):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
[4]夏易曼娜,李虎成.腹腔镜下宫颈癌根治术与传统开腹手术的对比研究[J].医学信息,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
　XIA Yi-manna,LI Hu-cheng.Comparative Study of Laparoscopic Radical Resection of Cervical Cancer and Traditional Open Surgery[J].Journal of Medical Information,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
[5]杨 军,王翠平,李 龙,等.义安区体检HPV-DNA筛查结果分析[J].医学信息,2018,31(14):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
　YANG Jun,WANG Cui-ping,LI Long,et al.Analysis of the Results of HPV-DNA Screening in the Medical Examination of Yian District[J].Journal of Medical Information,2018,31(12):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
[6]王双英,张 娜,刘 芳.具有高危复发因素的早期宫颈癌术后辅助治疗进展[J].医学信息,2018,31(15):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
　WANG Shuang-ying,ZHANG Na,LIU Fang.Advances in Postoperative Adjuvant Therapy for Early Cervical Cancer with High Risk of Recurrence[J].Journal of Medical Information,2018,31(12):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
[7]聂小凤,翟慧慧,冷天艳,等.宫颈脱落细胞miR34a检测在HR-HPV阳性患者 分流中的作用分析[J].医学信息,2018,31(16):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
　NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Journal of Medical Information,2018,31(12):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
[8]吴晓玲,周桂华.miR-187在宫颈癌中的表达与临床病理关系的研究[J].医学信息,2018,31(16):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
　WU Xiao-ling,ZHOU Gui-hua.Expression of miR-187 in Cervical Cancer and Its Relationship with Clinicopathological Features[J].Journal of Medical Information,2018,31(12):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
[9]夏为书,彭莉贞,钟清玲.我国宫颈癌患者配偶生活质量评价的研究现状[J].医学信息,2018,31(23):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
　XIA Wei-shu,PENG Li-zhen,ZHONG Qing-ling.Research Status of Spouse Quality of Life Evaluation of Cervical Cancer Patients in China[J].Journal of Medical Information,2018,31(12):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
[10]邢 均.全身麻醉联合硬膜外麻醉在宫颈癌手术中的应用及效果评价[J].医学信息,2019,32(01):122.[doi:10.3969/j.issn.1006-1959.2019.01.037]
　XING Jun.Application and Evaluation of General Anesthesia Combined with Epidural Anesthesia in[J].Journal of Medical Information,2019,32(12):122.[doi:10.3969/j.issn.1006-1959.2019.01.037]

更新日期/Last Update: 1900-01-01